Dark

SGMO
Sangamo Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

May 20, 2025 3:59:30 PM EDT

0.4996USD+0.221%(+0.0011)3,018,118

0.00Bid 0.00Ask 0.0000Spread

Pre-market

May 20, 2025 9:22:30 AM EDT

0.4979USD-0.120%(-0.0006)14,610

After-hours

May 20, 2025 4:53:30 PM EDT

0.5000USD+0.080%(+0.0004)10,310

OverviewOptionsHistoricalExchangesShortsNews

Jan 6, 2022

09:04AM EST Genomic medicines company Sangamo Therapeutics, Inc. (SGMO) announced Thursday that French drug major Sanofi (SNYNF, SNY) will be transitioning its rights and obligations related to SAR445136 back to Sangamo over the first half of 2022. RTTNews

08:33AM EST Sangamo Reports Transition Of SAR445136 Sickle Cell Disease Program From Sanofi To Sangamo RTTNews

08:00AM EST Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo Business Wire

06:59AM EST Sangamo Therapeutics Announces Sanofi Notified Co. Of Its Termination Of Collaboration Agreement, Effective June 28, 2022 Benzinga

Jan 4, 2022

05:00PM EST Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference Business Wire

Dec 12, 2021

05:10PM EST Pfizer, Sangamo Announced Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy Presented at ASH 2021 Benzinga

04:30PM EST Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy Business Wire

09:58AM EST Sangamo Therapeutics Announced Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease at ASH 2021; Said All Four Treated Patients Experienced Increases In Total Hemoglobin, Fetal Hemoglobin And Percent F Cells Benzinga

09:05AM EST Sangamo Therapeutics Reports Updated Preliminary Proof-of-concept Data From Phase 1/2 PRECIZN-1 Study Of SAR44513 RTTNews

09:00AM EST Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease Business Wire

Nov 22, 2021

07:00AM EST Organogenesis Appoints Prathyusha Duraibabu to Board of Directors GlobeNewswire Inc

Nov 9, 2021

08:30AM EST Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Nov 4, 2021

09:26AM EDT Sangamo Therapeutics Q3 EPS $(0.33) Beats $(0.34) Estimate, Sales $28.56M Beat $25.19M Estimate Benzinga

09:14AM EDT Sangamo Therapeutics Q3 Attributable Loss $47.7 Mln Or $0.33/shr Vs. Loss $1.6 Mln Or $0.01/shr Prior Year RTTNews

09:05AM EDT Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results Business Wire

08:59AM EDT Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability, Sustained Elevated -Gal A Enzyme Activity In Patients With Fabry Disease Benzinga

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

08:17AM EDT Sangamo : Phase 1/2 Data Shows Tolerability And Sustained Elevated -Gal A Enzyme Activity In Patients With Fabry Disease RTTNews

08:00AM EDT Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated -Gal A Enzyme Activity in Patients With Fabry Disease Business Wire

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

04:30PM EDT Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast Business Wire

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Sep 23, 2021

10:57AM EDT Sangamo Thearpeutics US Patent & Trademark Office Abstract For Co.'s 'NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS' Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 10, 2021

09:41AM EDT Sangamo Therapeutics 'Long-Term Follow-up of Subjects Who Were Treated With ST-920' Posted To ClinicalTrials.Gov; Study Enrolling By Invitation Benzinga

Aug 31, 2021

08:30AM EDT Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 9, 2021

04:30PM EDT Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference Business Wire

Aug 5, 2021

04:32PM EDT Sangamo Therapeutics Q2 EPS $(0.33) Misses $(0.31) Estimate, Sales $27.87M Beat $26.48M Estimate Benzinga

04:02PM EDT Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results Business Wire

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

04:31PM EDT Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast Business Wire

May 24, 2021

04:29PM EDT Sangamo Therapeutics Appoints Prathyusha Duraibabu As CFO RTTNews

04:16PM EDT Sangamo Therapeutics Names Prathyusha Duraibabu As CFO Benzinga

04:15PM EDT Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer Business Wire

May 21, 2021

08:30AM EDT Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference Business Wire

May 4, 2021

04:12PM EDT Sangamo Therapeutics Q1 EPS $(0.32) Misses $(0.30) Estimate, Sales $26.28M Beat $23.98M Estimate Benzinga

04:01PM EDT Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results Business Wire

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 Benzinga

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

06:34AM EDT RBC Capital Initiates Coverage On Sangamo Therapeutics with Outperform Rating, Announces Price Target of $22 Benzinga

May 3, 2021

04:50PM EDT Sangamo Therapeutics To Present At 2021 RBC Capital Markets Global Healthcare Conference May 18 Benzinga

04:30PM EDT Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Apr 27, 2021

04:52PM EDT Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy Benzinga

04:15PM EDT Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast Business Wire

Mar 25, 2021

08:30AM EDT Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Business Wire

Mar 17, 2021

04:34PM EDT Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease Benzinga

Feb 24, 2021

04:05PM EST Sangamo Therapeutics Q4 EPS $(0.29) Misses $(0.21) Estimate, Sales $25.80M Miss $32.15M Estimate Benzinga

04:01PM EST Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Business Wire

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 18, 2021

04:15PM EST Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Feb 17, 2021

04:15PM EST Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast Business Wire

Feb 2, 2021

09:46AM EST Sangamo BioSciences Awarded U.S. Patent 10,907,175 'Isolated human cell with an inactivated glucocorticoid receptor gene' Benzinga

Feb 1, 2021

04:09PM EST Sangamo Therapeutics Appoints Rob Schott As Head Of Development And Jason Fortenot As Chief Scientific Officer Benzinga

04:05PM EST Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer Business Wire

Jan 6, 2021

04:10PM EST Sangamo Therapeutics Reports CFO Sung Lee Leaving Co. Benzinga

04:10PM EST Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee Business Wire

10:14AM EST Benzinga's Top Upgrades, Downgrades For January 6, 2021 Benzinga

07:40AM EST Stifel Initiates Coverage On Sangamo Therapeutics with Hold Rating, Announces Price Target of $16 Benzinga

Jan 5, 2021

08:00AM EST Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 16, 2020

06:13AM EST HC Wainwright & Co. Assumes Sangamo Therapeutics at Buy, Announces Price Target of $25 Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 7, 2020

07:15AM EST Pfizer, Sangamo Report Encouraging Findings From Phase 1/2 RTTNews

07:07AM EST Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy Benzinga

07:03AM EST Pfizer, Sangamo Announce Updated Follow-up Data From Phase 1/2 Alta Study Of Giroctocogene Fitelparvovec RTTNews

07:00AM EST Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy Business Wire

Nov 24, 2020

08:19AM EST Cramer Advises Viewers On Ballard Power Systems, Blink Charging And More Benzinga

Nov 5, 2020

08:00AM EST Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Nov 4, 2020

04:11PM EST Sangamo Therapeutics Q3 EPS $(0.01) Up From $(0.24) YoY, Sales $57.76M Up From $21.96M YoY Benzinga

04:01PM EST Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results Business Wire

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 28, 2020

04:15PM EDT Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast Business Wire

Oct 23, 2020

11:20AM EDT Sangamo Therapeutics Option Alert: Feb 19 $13 Calls Sweep (32) near the Ask: 695 @ $0.8 vs 83 OI; Earnings 11/4 After Close [est] Ref=$10.65 Benzinga

Oct 7, 2020

10:19AM EDT Shares of Sangamo Therapeutics Inc. (SGMO) are currently trading at $10.00, up 30 cents or 3.09% Wednesday morning. The stock has been trading in the range of $4.81 - $13.20 for the past one year, with trading volume of over 315K versus an average volume of 1.62 million shares. RTTNews

06:58AM EDT Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO) announced that the first participant has been dosed in the phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A patients. As per the terms of the collaboration deal, Sangamo has now earned a $30 million milestone payment. RTTNews

06:50AM EDT Pfizer, Sangamo Dose First Participant In Phase 3 AFFINE Study Of Giroctocogene Fitelparvovec For Hemophilia A Patients RTTNews

06:47AM EDT Pfizer and Sangamo Dose First Participant In Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment Benzinga

Sep 28, 2020

08:30AM EDT Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Sep 11, 2020

08:35AM EDT Sangamo Therapeutics Appoints Kenneth Hillan To Board RTTNews

08:30AM EDT Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors Business Wire

Sep 8, 2020

01:01PM EDT B of A Securities Reinstates Buy on Sangamo Therapeutics, Announces $20 Price Target Benzinga

Sep 2, 2020

04:15PM EDT Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire

Aug 19, 2020

01:47PM EDT Truist Securities Says Sangamo Therapeutics' SB-525 Could be Closer To Roctavian Launch Benzinga

Aug 10, 2020

08:30AM EDT Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Business Wire

Aug 5, 2020

04:09PM EDT Sangamo Therapeutics Q2 EPS $(0.26), Same YoY, Sales $21.55M Up From $17.55M YoY Benzinga

04:01PM EDT Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results Business Wire

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 30, 2020

07:25AM EDT Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders; Sangamo Will Receive A $75M Upfront; Eligible To Receive Up To $720M In Potential Milestones Benzinga

07:00AM EDT Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders Business Wire

Jul 29, 2020

04:15PM EDT Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast Business Wire